Freestyle Libre 3 CGM System
Performance you can count on2
Real-time glucose readings are sent every minute to your smartphone‡ and can be viewed with a quick glance§.
ACCURATE
The most accurate2 14-day CGM system to help reduce time spent in hypoglycemia*3 and improve overall glucose control*3,4
DISCREET
The world’s smallest5, thinnestII, and most discreet5 sensor—smaller than two stacked pennies5
EASY
Painless to apply5 and wear5 with a simple 1-piece applicator
RELIABLE
Optional, real-time glucose alarms¶ let you know the minute your glucose is too high or too low
CGM = continuous glucose monitoring
At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.
* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore, the study data is applicable to both products.
‡ The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView.
§ 60-minute warm-up required when starting the sensor.
II Among patient-applied sensors.
¶ Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User’s Manual for more information.
References: 1. Fokkert, Marion, et al. “Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).” BMJ Open Diabetes Research and Care 7 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 2. FreeStyle Libre 3 User’s Manual. 3. Bolinder, Jan, et al. “Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.” The Lancet 10057, no. 388 (2016): 2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 4. Yaron, Marianna, et al. “Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes.” Diabetes Care 42, no. 7 (2019); 1178-1184. https://doi.org/10.2337/dc18-0166. 5. Data on File. Abbott Diabetes Care.
ADC-56218 v3.0 09/22
Important Safety Information
FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
The circular shape of the sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-29111 v11.0 05/22